CGTX Relative Valuation
CGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGTX is overvalued; if below, it's undervalued.
Historical Valuation
Cognition Therapeutics Inc (CGTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.74. The fair price of Cognition Therapeutics Inc (CGTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.46
Fair
-5.64
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Cognition Therapeutics Inc. (CGTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.99
EV/EBIT
Cognition Therapeutics Inc. (CGTX) has a current EV/EBIT of -1.99. The 5-year average EV/EBIT is -1.11. The thresholds are as follows: Strongly Undervalued below -5.63, Undervalued between -5.63 and -3.37, Fairly Valued between 1.15 and -3.37, Overvalued between 1.15 and 3.41, and Strongly Overvalued above 3.41. The current Forward EV/EBIT of -1.99 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Cognition Therapeutics Inc. (CGTX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-4.12
P/OCF
Cognition Therapeutics Inc. (CGTX) has a current P/OCF of -4.12. The 5-year average P/OCF is -4.18. The thresholds are as follows: Strongly Undervalued below -17.00, Undervalued between -17.00 and -10.59, Fairly Valued between 2.23 and -10.59, Overvalued between 2.23 and 8.64, and Strongly Overvalued above 8.64. The current Forward P/OCF of -4.12 falls within the Historic Trend Line -Fairly Valued range.
-2.38
P/FCF
Cognition Therapeutics Inc. (CGTX) has a current P/FCF of -2.38. The 5-year average P/FCF is -1.38. The thresholds are as follows: Strongly Undervalued below -4.35, Undervalued between -4.35 and -2.87, Fairly Valued between 0.10 and -2.87, Overvalued between 0.10 and 1.58, and Strongly Overvalued above 1.58. The current Forward P/FCF of -2.38 falls within the Historic Trend Line -Fairly Valued range.
Cognition Therapeutics Inc (CGTX) has a current Price-to-Book (P/B) ratio of 3.55. Compared to its 3-year average P/B ratio of 2.85 , the current P/B ratio is approximately 24.70% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 53.54% higher. Cognition Therapeutics Inc (CGTX) has a Forward Free Cash Flow (FCF) yield of approximately -22.76%. Compared to its 3-year average FCF yield of -59.82%, the current FCF yield is approximately -61.95% lower. Relative to its 5-year average FCF yield of -45.61% , the current FCF yield is about -50.10% lower.
3.55
P/B
Median3y
2.85
Median5y
2.31
-22.76
FCF Yield
Median3y
-59.82
Median5y
-45.61
Competitors Valuation Multiple
The average P/S ratio for CGTX's competitors is 3.35, providing a benchmark for relative valuation. Cognition Therapeutics Inc Corp (CGTX) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CGTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CGTX in the past 1 year is driven by Unknown.
People Also Watch
GIFT
Giftify Inc
1.09USD
0.00%
CRIS
Curis Inc
0.8649USD
-13.50%
ANY
Sphere 3D Corp
0.3417USD
-3.39%
TURB
Turbo Energy SA
1.1007USD
5.87%
HOVR
New Horizon Aircraft Ltd
2.02USD
9.19%
BGI
Birks Group Inc
0.9564USD
3.80%
HUBC
Hub Cyber Security Ltd
0.3414USD
-6.06%
PMEC
Primech Holdings Ltd
1.05USD
1.94%
AXIL
AXIL Brands Inc
6.25USD
0.48%
Frequently Asked Questions
Is Cognition Therapeutics Inc (CGTX) currently overvalued or undervalued?
Cognition Therapeutics Inc (CGTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.74. The fair price of Cognition Therapeutics Inc (CGTX) is between to according to relative valuation methord.
What is Cognition Therapeutics Inc (CGTX) fair value?
CGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cognition Therapeutics Inc (CGTX) is between to according to relative valuation methord.
How does CGTX's valuation metrics compare to the industry average?
The average P/S ratio for CGTX's competitors is 3.35, providing a benchmark for relative valuation. Cognition Therapeutics Inc Corp (CGTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cognition Therapeutics Inc (CGTX) as of Jan 07 2026?
As of Jan 07 2026, Cognition Therapeutics Inc (CGTX) has a P/B ratio of 3.55. This indicates that the market values CGTX at 3.55 times its book value.
What is the current FCF Yield for Cognition Therapeutics Inc (CGTX) as of Jan 07 2026?
As of Jan 07 2026, Cognition Therapeutics Inc (CGTX) has a FCF Yield of -22.76%. This means that for every dollar of Cognition Therapeutics Inc’s market capitalization, the company generates -22.76 cents in free cash flow.
What is the current Forward P/E ratio for Cognition Therapeutics Inc (CGTX) as of Jan 07 2026?
As of Jan 07 2026, Cognition Therapeutics Inc (CGTX) has a Forward P/E ratio of -5.64. This means the market is willing to pay $-5.64 for every dollar of Cognition Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cognition Therapeutics Inc (CGTX) as of Jan 07 2026?
As of Jan 07 2026, Cognition Therapeutics Inc (CGTX) has a Forward P/S ratio of 0.00. This means the market is valuing CGTX at $0.00 for every dollar of expected revenue over the next 12 months.